Lexaria Bioscience (LEXX)
Market Price (11/5/2026): $3.96 | Market Cap: $8.3 MilSector: Health Care | Industry: Biotechnology
Lexaria Bioscience (LEXX)
Market Price (11/5/2026): $3.96Market Cap: $8.3 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -52% Megatrend and thematic driversMegatrends include Precision Medicine, and Health & Wellness Trends. Themes include Biopharmaceutical R&D, and Nutritional Supplements. | Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 15% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -7.7 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -3973% Stock price has recently run up significantly6M Rtn6 month market price return is 503%, 12M Rtn12 month market price return is 267% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -69%, Rev Chg QQuarterly Revenue Change % is null Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 188% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -3828%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -3880% Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 904% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -119% High stock price volatilityVol 12M is 815% Key risksLEXX key risks include [1] substantial doubt about its ability to continue as a going concern due to significant financial losses and a high cash burn rate, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -52% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Health & Wellness Trends. Themes include Biopharmaceutical R&D, and Nutritional Supplements. |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 15% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -7.7 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -3973% |
| Stock price has recently run up significantly6M Rtn6 month market price return is 503%, 12M Rtn12 month market price return is 267% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -69%, Rev Chg QQuarterly Revenue Change % is null |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 188% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -3828%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -3880% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 904% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -119% |
| High stock price volatilityVol 12M is 815% |
| Key risksLEXX key risks include [1] substantial doubt about its ability to continue as a going concern due to significant financial losses and a high cash burn rate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Lexaria Bioscience (LEXX) stock has lost about 30% since 7/31/2026 because of the following key factors:
1. Weak Financial Performance and Going Concern Warning in Fiscal Q3 2026.
Lexaria Bioscience reported a significant earnings miss for fiscal Q3 2026 (ended May 31, 2026) with an Earnings Per Share (EPS) of -$1.20, missing analysts' estimates by 33.33%. The company's revenue for the nine months ended May 31, 2026, dramatically fell to $20,000 from $531,923 in the prior year, primarily due to the expiration of a key licensing contract and reduced business-to-business (B2B) product sales. Crucially, management disclosed "substantial doubt about the company's ability to continue as a going concern beyond early fiscal 2027 without additional capital or partnerships". This severe financial outlook and concern over viability, reported just before the analysis period began, significantly contributed to negative investor sentiment.
2. Nasdaq Delisting Threat and Subsequent Reverse Stock Split.
In early August 2026, Lexaria received a notification from Nasdaq indicating potential delisting due to its failure to maintain the $1.00 minimum bid price requirement. To address this compliance issue, the company enacted a one-for-fifteen (1-15) reverse stock split on August 3, 2026, successfully bringing its share price above the minimum threshold. While Lexaria regained compliance by August 17, 2026, reverse stock splits are often perceived negatively by the market, signaling underlying financial weakness and potentially leading to diminished investor confidence and reduced trading liquidity.
Show more
Lexaria Bioscience (LEXX) stock has lost about 30% since 7/31/2026 because of the following key factors:
1. Weak Financial Performance and Going Concern Warning in Fiscal Q3 2026.
Lexaria Bioscience reported a significant earnings miss for fiscal Q3 2026 (ended May 31, 2026) with an Earnings Per Share (EPS) of -$1.20, missing analysts' estimates by 33.33%. The company's revenue for the nine months ended May 31, 2026, dramatically fell to $20,000 from $531,923 in the prior year, primarily due to the expiration of a key licensing contract and reduced business-to-business (B2B) product sales. Crucially, management disclosed "substantial doubt about the company's ability to continue as a going concern beyond early fiscal 2027 without additional capital or partnerships". This severe financial outlook and concern over viability, reported just before the analysis period began, significantly contributed to negative investor sentiment.
2. Nasdaq Delisting Threat and Subsequent Reverse Stock Split.
In early August 2026, Lexaria received a notification from Nasdaq indicating potential delisting due to its failure to maintain the $1.00 minimum bid price requirement. To address this compliance issue, the company enacted a one-for-fifteen (1-15) reverse stock split on August 3, 2026, successfully bringing its share price above the minimum threshold. While Lexaria regained compliance by August 17, 2026, reverse stock splits are often perceived negatively by the market, signaling underlying financial weakness and potentially leading to diminished investor confidence and reduced trading liquidity.
3. Share Dilution from Warrant Exercise at a Reduced Price.
In September 2026, Lexaria completed the exercise of certain outstanding warrants, which generated approximately $5.9 million in gross proceeds for the company. However, these warrants were exercised at a reduced price of $12.92 per share, and new unregistered Series A and Series B warrants were issued in the process. Despite bringing in capital, the exercise of warrants at a significantly reduced price compared to their original terms, and the issuance of additional warrants, can lead to concerns about share dilution for existing shareholders, thereby negatively impacting the stock's valuation.
4. Bearish Technical Signals and Management's Acknowledgment of Trading Pressure.
Lexaria's stock exhibited several bearish technical indicators throughout October 2026. On October 8, 2026, the 50-day moving average for LEXX dropped below the 200-day moving average, typically signaling a long-term bearish trend. Additionally, the Aroon Indicator entered a downward trend on October 22, 2026, suggesting strong potential for further price declines. These technical indicators coincided with comments made by CEO Rich Christopher in September 2026, who acknowledged that the stock price was "under significant pressure by what can only be described as aggressive/perplexing trading activity" despite positive business developments, implying ongoing external selling pressure and market apprehension.
Show less
Stock Movement Drivers
Fundamental Drivers
The -30.6% change in LEXX stock from 7/31/2026 to 11/4/2026 was primarily driven by a -30.6% change in the company's P/S Multiple.| (LTM values as of) | 7312026 | 11042026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.86 | 4.07 | -30.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | 50.0 | 34.7 | -30.6% |
| Shares Outstanding (Mil) | 2 | 2 | 0.0% |
| Cumulative Contribution | -30.6% |
Market Drivers
7/31/2026 to 11/4/2026| Return | Correlation | |
|---|---|---|
| LEXX | -30.6% | |
| Market (SPY) | 2.6% | 18.9% |
| Sector (XLV) | 16.7% | 24.1% |
Fundamental Drivers
The 517.6% change in LEXX stock from 4/30/2026 to 11/4/2026 was primarily driven by a 1088.9% change in the company's P/S Multiple.| (LTM values as of) | 4302026 | 11042026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.66 | 4.07 | 517.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | -47.3% |
| P/S Multiple | 2.9 | 34.7 | 1088.9% |
| Shares Outstanding (Mil) | 2 | 2 | -1.5% |
| Cumulative Contribution | 517.6% |
Market Drivers
4/30/2026 to 11/4/2026| Return | Correlation | |
|---|---|---|
| LEXX | 517.6% | |
| Market (SPY) | 7.0% | 9.2% |
| Sector (XLV) | 30.5% | -4.8% |
Fundamental Drivers
The 299.0% change in LEXX stock from 10/31/2025 to 11/4/2026 was primarily driven by a 1617.4% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 11042026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.02 | 4.07 | 299.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 0 | -68.5% |
| P/S Multiple | 2.0 | 34.7 | 1617.4% |
| Shares Outstanding (Mil) | 1 | 2 | -26.2% |
| Cumulative Contribution | 299.0% |
Market Drivers
10/31/2025 to 11/4/2026| Return | Correlation | |
|---|---|---|
| LEXX | 299.0% | |
| Market (SPY) | 13.4% | 7.1% |
| Sector (XLV) | 33.2% | -3.0% |
Fundamental Drivers
The 194.9% change in LEXX stock from 10/31/2023 to 11/4/2026 was primarily driven by a 1695.2% change in the company's P/S Multiple.| (LTM values as of) | 10312023 | 11042026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.38 | 4.07 | 194.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | -36.7% |
| P/S Multiple | 1.9 | 34.7 | 1695.2% |
| Shares Outstanding (Mil) | 0 | 2 | -74.0% |
| Cumulative Contribution | 194.9% |
Market Drivers
10/31/2023 to 11/4/2026| Return | Correlation | |
|---|---|---|
| LEXX | 194.9% | |
| Market (SPY) | 89.7% | 5.2% |
| Sector (XLV) | 59.5% | -0.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| LEXX Return | -46% | -39% | -49% | 68% | -71% | 560% | -46% |
| Peers Return | -19% | -34% | 25% | 53% | 37% | -22% | 10% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 11% | 102% |
Monthly Win Rates [3] | |||||||
| LEXX Win Rate | 33% | 25% | 42% | 50% | 42% | 55% | |
| Peers Win Rate | 42% | 45% | 43% | 60% | 53% | 49% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 36% | |
Max Drawdowns [4] | |||||||
| LEXX Max Drawdown | -54% | -60% | -80% | -68% | -77% | -82% | |
| Peers Max Drawdown | -48% | -59% | -49% | -51% | -41% | -50% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: AQST, LPCN, JAZZ, ABBV, CRBP.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/4/2026 (YTD)
How Low Can It Go
| Event | LEXX | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -42.1% | -18.8% |
| % Gain to Breakeven | 72.6% | 23.1% |
| Time to Breakeven | 423 days | 79 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -74.7% | -6.7% |
| % Gain to Breakeven | 296.0% | 7.1% |
| Time to Breakeven | 283 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -56.1% | -24.5% |
| % Gain to Breakeven | 127.7% | 32.4% |
| Time to Breakeven | 652 days | 427 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -51.0% | -12.2% |
| % Gain to Breakeven | 104.2% | 13.9% |
| Time to Breakeven | 247 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -55.6% | -6.8% |
| % Gain to Breakeven | 125.0% | 7.3% |
| Time to Breakeven | 80 days | 15 days |
| 2013 Taper Tantrum | ||
| % Loss | -65.8% | -0.2% |
| % Gain to Breakeven | 192.7% | 0.2% |
| Time to Breakeven | 120 days | 1 days |
In The Past
Lexaria Bioscience's stock fell -42.1% during the 2025 US Tariff Shock. Such a loss loss requires a 72.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | LEXX | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -42.1% | -18.8% |
| % Gain to Breakeven | 72.6% | 23.1% |
| Time to Breakeven | 423 days | 79 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -74.7% | -6.7% |
| % Gain to Breakeven | 296.0% | 7.1% |
| Time to Breakeven | 283 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -56.1% | -24.5% |
| % Gain to Breakeven | 127.7% | 32.4% |
| Time to Breakeven | 652 days | 427 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -51.0% | -12.2% |
| % Gain to Breakeven | 104.2% | 13.9% |
| Time to Breakeven | 247 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -55.6% | -6.8% |
| % Gain to Breakeven | 125.0% | 7.3% |
| Time to Breakeven | 80 days | 15 days |
| 2013 Taper Tantrum | ||
| % Loss | -65.8% | -0.2% |
| % Gain to Breakeven | 192.7% | 0.2% |
| Time to Breakeven | 120 days | 1 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -44.4% | -15.4% |
| % Gain to Breakeven | 80.0% | 18.2% |
| Time to Breakeven | 117 days | 125 days |
In The Past
Lexaria Bioscience's stock fell -42.1% during the 2025 US Tariff Shock. Such a loss loss requires a 72.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Lexaria Bioscience (LEXX)
Lexaria Bioscience Corp. (LEXX) is a biotechnology company specializing in advanced drug delivery solutions. Its core technology is a patented platform called DehydraTECH, which is designed to significantly improve how active pharmaceutical ingredients (APIs) are absorbed into the bloodstream, particularly when administered orally. This technology enhances the bioavailability and overall effectiveness of various compounds.
DehydraTECH offers several key benefits, including a dramatic increase in bio-absorption—demonstrated to be 5-10 times, and in some cases up to 27 times, higher for cannabinoids and nicotine compared to standard formulations. It also reduces the time it takes for drugs to take effect, from hours to just minutes, and effectively masks undesirable tastes. Furthermore, DehydraTECH can facilitate the delivery of drugs across the blood-brain barrier. While currently applied to cannabinoids and nicotine, the technology is also being evaluated for use with anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and other compounds.
Lexaria operates a licensed in-house research laboratory and boasts a strong intellectual property portfolio with 23 granted patents and approximately 50 patents pending worldwide. The company's business model revolves around the development and licensing of its DehydraTECH technology to pharmaceutical companies and other industries that aim to improve the performance and user experience of their orally delivered products, thereby serving markets focused on enhancing drug efficacy and patient compliance.
AI Analysis | Feedback
Here are 1-3 brief analogies to describe Lexaria Bioscience (LEXX):
- Lexaria Bioscience is like the Intel of drug delivery, providing a core technology (DehydraTECH) that makes various drugs work faster and more effectively within the body.
- Lexaria Bioscience is like the Gore-Tex for pharmaceuticals, developing a specialized ingredient technology (DehydraTECH) that enhances the performance, speed, and taste of many different drug products.
AI Analysis | Feedback
- DehydraTECH Drug Delivery Technology: A patented technology designed to improve the oral absorption, onset time, and taste of various active pharmaceutical ingredients.
- Cannabinoid and Nicotine Formulations: Utilizes DehydraTECH to enhance the delivery and bioavailability of cannabinoids and nicotine in product formulations.
- Pharmaceutical Drug Formulations: Applies DehydraTECH to develop improved oral delivery for anti-viral drugs, NSAIDs, PDE5 inhibitors, and other pharmaceutical compounds, including those requiring blood-brain barrier penetration.
AI Analysis | Feedback
Lexaria Bioscience Corp. operates as a biotechnology company primarily engaged in licensing its patented DehydraTECH drug delivery technology to other businesses. Therefore, its major customers are other companies in the pharmaceutical, nutraceutical, and consumer goods industries that seek to incorporate Lexaria's technology into their products to improve bio-absorption, reduce onset time, or mask unwanted tastes.
However, the provided background information does not specify the names of Lexaria Bioscience's major customer companies or their public symbols.
AI Analysis | Feedback
AI Analysis | Feedback
Richard Christopher, Chief Executive Officer
Richard Christopher was appointed Chief Executive Officer of Lexaria Bioscience Corp. effective August 31, 2024. He brings over 30 years of experience in the medical device and pharmaceutical industries. His career highlights include a successful tenure at DUSA Pharmaceuticals, Inc., where he was part of the team that led the company from startup to profitability and its eventual acquisition by Sun Pharmaceuticals Industries Ltd. Before joining Lexaria, Christopher served as Chief Financial Officer at InVivo Therapeutics, and held similar CFO roles at iCAD, Inc. and Caliber Imaging & Diagnostics, Inc.
Michael Shankman, CPA, Chief Financial Officer
Michael Shankman was appointed Chief Financial Officer of Lexaria Bioscience Corp. effective October 1, 2024. He previously worked with Lexaria as a designated contractor, assisting with financial reporting and the 2023 audit. From 2021 to 2024, Mr. Shankman provided outsourced CFO and Controller services for a national service provider, gaining extensive experience with both public and private companies across various industries. His background includes financial leadership positions in biotechnology, medical devices, and software as a service.
John Docherty, President and Chief Scientific Officer
John Docherty became President of Lexaria in the spring of 2015 and joined its board of directors a year later. He is a senior operations and management executive with over 20 years of experience in the pharmaceutical and biopharmaceutical sectors. Prior to Lexaria, he was President and Chief Operating Officer of Helix BioPharma Corp. (TSX: HBP), where he led pharmaceutical development programs. He has also served as president and a board member of PharmaDerm Laboratories Ltd., a Canadian drug delivery company. Mr. Docherty is a named inventor on issued and pending patents.
Chris Bunka, Chairman of the Board, Executive Strategic Advisor
Chris Bunka is the Chairman of the Board and Executive Strategic Advisor for Lexaria Bioscience Corp. He previously served as the CEO of Lexaria and has been Chairman of the Board since 2006, playing a primary role in the company's shift towards bioscience. A serial entrepreneur, he has been involved in numerous private and public companies since the late 1980s. He possesses extensive experience in capital markets, corporate governance, project acquisition, and corporate finance. Bunka was also Chairman, CEO, Secretary & Treasurer of Enertopia Corp. and Golden Aria Corp., and President & CEO of Newsgurus.com, Inc.
AI Analysis | Feedback
The key risks for Lexaria Bioscience (LEXX) are primarily centered around the successful development and commercialization of its DehydraTECH drug delivery technology, its financial sustainability, and the protection of its intellectual property.
- Clinical Trial and Regulatory Risk: As a biotechnology company, Lexaria Bioscience's success is heavily dependent on the successful outcomes of its ongoing and future clinical trials for various drug applications of its DehydraTECH technology. Failures in clinical trials, unexpected adverse effects, or an inability to meet stringent government regulatory requirements for drugs (including GLP-1 drugs, antivirals, cannabinoids, and nicotine) could significantly impede the commercialization of its technology and products. The company is actively evaluating its technology for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), and PDE5 inhibitors, among others, meaning many applications are still in development stages where trial outcomes are critical.
- Financial Viability and Cash Burn: Lexaria Bioscience has reported significant net losses, including $11.9 million for the fiscal year ending August 31, 2025, and $3.8 million for the third quarter of fiscal 2025, indicating ongoing financial challenges. As of November 2024, the company had a cash runway of approximately 15 months, based on its cash reserves of US$8.1 million and a cash burn of US$6.7 million over the trailing twelve months. While its cash position has reportedly improved, and it raised $9.5 million in 2025 for prospective 2026 development, the company is not yet generating significant revenue (US$497k in the last year). This ongoing cash burn necessitates continued financing, posing a risk to the company's ability to fund its research and development, as well as its path to commercialization.
- Intellectual Property Risk: Lexaria Bioscience relies heavily on its patented DehydraTECH drug delivery technology, holding 23 granted patents and approximately 50 pending worldwide. More recently, it was granted 10 patents, totaling 56 worldwide. The strength, enforceability, and continued expansion of this intellectual property portfolio are crucial. Challenges to existing patents, the expiration of key patents, or the inability to secure new patents for future innovations could undermine the company's competitive advantage and allow competitors to develop similar drug delivery solutions.
AI Analysis | Feedback
AI Analysis | Feedback
Lexaria Bioscience Corp. (LEXX) focuses on its patented DehydraTECH drug delivery technology, which enhances the oral delivery of various active pharmaceutical ingredients. The addressable markets for their main product applications are substantial, spanning several therapeutic areas globally and in key regions.
Cannabinoids
The global cannabinoids market was valued at approximately USD 22.1 billion in 2021 and is projected to reach USD 154.2 billion by the end of 2031, growing at a compound annual growth rate (CAGR) of 22.2% from 2022 to 2031. Another report estimates the global cannabis market size at USD 45.0 billion in 2026, projected to reach USD 86.6 billion by 2031, with a 14.0% CAGR. North America dominated the global market in 2021 and is projected to expand at an 18% CAGR from 2022 to 2031. The global cannabidiol (CBD) market size was estimated at USD 10.38 billion in 2025 and is predicted to increase to approximately USD 43.81 billion by 2035, expanding at a CAGR of 15.49% from 2026 to 2035. North America held the largest market share of 87% in the CBD market in 2025.
Nicotine
The global nicotine replacement therapy (NRT) market was valued at USD 80.53 billion in 2024 and is projected to reach USD 353.86 billion by 2034, growing at a CAGR of 15.95% from 2025 to 2034. Another source reported the global NRT market at USD 59.4 billion in 2022, with a projection to reach USD 198.7 billion by 2030 at a CAGR of 16.3% from 2023 to 2030. North America is expected to attain the fastest rate of growth during the forecast period. In 2025, North America generated USD 1.43 billion, contributing 46.72% to global market revenue. The U.S. NRT market is projected to reach USD 1.34 billion by 2026.
Anti-viral Drugs
The global antiviral drugs market was estimated at USD 60.6 billion in 2024. It is expected to grow from USD 62 billion in 2025 to USD 85.4 billion in 2034, at a CAGR of 3.6%. Other estimates place the global market size at USD 65.13 billion in 2026, projected to reach approximately USD 89.86 billion by 2035, expanding at a CAGR of 3.64% from 2026 to 2035. North America dominated the antiviral drugs market in 2025. The U.S. antiviral drugs market was valued at USD 22.2 billion in 2024.
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
The global non-steroidal anti-inflammatory drugs (NSAIDs) market size was estimated at USD 22.58 billion in 2024 and is projected to reach USD 31.29 billion by 2030, growing at a CAGR of 5.66% from 2025 to 2030. Another report indicated the market size was USD 22.3 billion in 2024 and is projected to grow to USD 39.2 billion by 2034 at a CAGR of 5.8% from 2025 to 2034. North America held the largest share of 42.92% in the NSAIDs market in 2024 and is expected to register a lucrative growth rate. In 2019, North America dominated the NSAIDs market with a market share of 44.03%.
PDE5 Inhibitors (Erectile Dysfunction Drugs)
The global erectile dysfunction drugs market size was estimated at USD 2.93 billion in 2024 and is predicted to increase to approximately USD 6.74 billion by 2034, expanding at a CAGR of 8.69% from 2025 to 2034. Another report states the global market was valued at USD 3.18 billion in 2024 and is set to reach USD 6.86 billion by 2034 at a CAGR of 8.9% from 2025 to 2034. North America dominated the erectile dysfunction drugs market in 2024 with a revenue share of 53%. The U.S. erectile dysfunction drugs market size was valued at USD 1.09 billion in 2024 and is expected to be worth around USD 2.55 billion by 2034 with a CAGR of 8.87% from 2025 to 2034.
AI Analysis | Feedback
Lexaria Bioscience Corp. (NASDAQ: LEXX) is expected to drive future revenue growth over the next two to three years through several key initiatives centered around its proprietary DehydraTECH drug delivery technology:
- Licensing of DehydraTECH for GLP-1 Drugs: Lexaria's most significant anticipated revenue driver is the potential licensing of its DehydraTECH technology for use with GLP-1 (glucagon-like peptide-1) drugs, such as semaglutide and liraglutide. The company is actively conducting human studies demonstrating that DehydraTECH can enhance the safety profile of these drugs by reducing gastrointestinal adverse events, potentially leading to increased patient acceptance and market share for oral formulations. Promising results from studies showing reductions in weight and blood sugar levels could lead to significant licensing agreements within this rapidly growing therapeutic area.
- Broad Application and Licensing Across Diverse Active Pharmaceutical Ingredients (APIs): Beyond GLP-1s, Lexaria's DehydraTECH platform has shown the ability to improve the bio-absorption and delivery of a wide range of APIs, including cannabinoids, nicotine, anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), and PDE5 inhibitors. Successful development and licensing deals across these various therapeutic areas will diversify and expand Lexaria's revenue streams.
- Expansion and Strengthening of Intellectual Property Portfolio: The continuous awarding of new patents strengthens Lexaria's intellectual property protection for its DehydraTECH technology. As of January 2026, the company was awarded six additional patents. A robust and growing patent portfolio provides a strong competitive advantage, enabling Lexaria to secure more favorable licensing agreements and potentially higher royalty rates from pharmaceutical partners, thereby driving future revenue growth.
AI Analysis | Feedback
Share Issuance
- In December 2025, Lexaria Bioscience announced a registered direct offering of approximately 2.66 million common shares at $1.315 per share, projected to generate approximately $3.5 million in gross proceeds.
- In September 2025, the company agreed to a registered direct offering of 2,666,667 common shares at $1.50 per share, anticipating gross proceeds of approximately $4.0 million.
- Lexaria Bioscience completed a follow-on equity offering in October 2024, raising $5 million through the issuance of 1.6 million shares.
Inbound Investments
- Lexaria Bioscience received approximately $3.5 million in gross proceeds from a registered direct offering of common stock in December 2025.
- A registered direct offering in September 2025 was expected to generate approximately $4.0 million in gross proceeds.
- In October 2024, the company completed a follow-on equity offering, resulting in $5 million in gross proceeds.
Capital Expenditures
- Lexaria Bioscience Corp. reported $0 in capital expenditures for the first quarter of 2026.
Peer Outperformance in Biotechnology
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 6 | 13.4% | 63.7% | 103.3% | CAH 490% · MCK 391% · COR 194% |
| Health Care Services | 20 | 44.0% | 33.3% | 11.6% | HIMS 220% · RDNT 148% · DGX 96% |
| Managed Health Care | 8 | 44.6% | 5.6% | 0.6% | OSCR 107% · HQY 59% · ELV 11% |
| Health Care Facilities | 25 | 16.9% | 18.4% | -3.0% | THC 302% · NHC 241% · EHC 202% |
| Health Care Equipment | 50 | 14.4% | 18.7% | -15.0% | UFPT 408% · GKOS 348% · PLSE 147% |
| Pharmaceuticals | 60 | -5.1% | 8.2% | -35.2% | LQDA 999% · KNSA 546% · LLY 448% |
| Health Care Supplies | 11 | 34.9% | 23.0% | -36.1% | LNTH 267% · HAE 76% · MMSI 33% |
| Life Sciences Tools & Services | 108 | -6.2% | -10.3% | -74.1% | AXGN 288% · NTRA 253% · MEDP 189% |
| Biotechnology ← | 364 | -21.1% | -31.5% | -81.7% | ELVN 1112% · TRVI 1046% · DNTH 930% |
| Health Care Technology | 21 | -23.4% | -56.5% | -82.3% | VEEV -3% · DOCS -52% |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| How Low Can Lexaria Bioscience Stock Really Go? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 3.91 |
| Mkt Cap | 0.3 |
| Rev LTM | 25 |
| Op Inc LTM | -10 |
| FCF LTM | -9 |
| FCF 3Y Avg | -7 |
| CFO LTM | -9 |
| CFO 3Y Avg | -7 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.7% |
| Rev Chg 3Y Avg | 6.3% |
| Rev Chg Q | -41.0% |
| QoQ Delta Rev Chg LTM | -9.7% |
| Op Inc Chg LTM | 16.2% |
| Op Inc Chg 3Y Avg | -23.5% |
| Op Mgn LTM | -114.1% |
| Op Mgn 3Y Avg | -92.8% |
| QoQ Delta Op Mgn LTM | -16.6% |
| CFO/Rev LTM | -81.4% |
| CFO/Rev 3Y Avg | -85.3% |
| FCF/Rev LTM | -83.3% |
| FCF/Rev 3Y Avg | -86.4% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Intellectual Property (IP) Licensing | 1 | 0 | 0 | 0 | 0 |
| Business-to-Business (B2B) | 0 | 0 | 0 | 0 | 0 |
| Corporate | 0 | 0 | 0 | ||
| Research & Development (R&D) | 0 | 0 | |||
| Total | 1 | 0 | 0 | 0 | 1 |
| $ Mil | 2022 |
|---|---|
| Intellectual Property (IP) Licensing | -0 |
| Business-to-Business (B2B) | -1 |
| Research & Development (R&D) | -2 |
| Corporate | -5 |
| Total | -7 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Intellectual Property (IP) Licensing | -12 | -6 | 0 | -0 | -2 |
| Business-to-Business (B2B) | -12 | -6 | -0 | -1 | -1 |
| Corporate | -3 | -5 | -1 | ||
| Research & Development (R&D) | -4 | -2 | |||
| Total | -24 | -12 | -7 | -7 | -4 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Corporate | 8 | 3 | 7 | 13 | 2 |
| Research & Development (R&D) | 0 | 0 | 0 | ||
| Intellectual Property (IP) Licensing | 0 | 0 | 0 | 1 | 1 |
| Business-to-Business (B2B) | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 3 | 8 | 13 | 3 |
Price Behavior
| Market Price | $4.07 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 06/26/2009 | |
| Distance from 52W High | -71.2% | |
| 50 Days | 200 Days | |
| DMA Price | $4.84 | $2.40 |
| DMA Trend | down | up |
| Distance from DMA | -16.0% | 69.5% |
| 3M | 1YR | |
| Volatility | 177.1% | 814.6% |
| Downside Capture | 607.57 | 300.68 |
| Upside Capture | 510.12 | 433.91 |
| Correlation (S&P 500) | 21.5% | 6.9% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.29 | 3.65 | 3.31 | 8.51 | 4.51 | 1.62 |
| Up Beta | -5.47 | -0.37 | 1.25 | 3.81 | 1.96 | 0.73 |
| Down Beta | 0.64 | 0.43 | 1.65 | -0.64 | -0.77 | 1.09 |
| Up Capture | 321% | 219% | 408% | 3312% | 2709% | 422% |
| Bmk +ve Days | 12 | 18 | 28 | 62 | 130 | 427 |
| Stock +ve Days | 12 | 20 | 32 | 57 | 120 | 347 |
| Down Capture | 111% | 623% | 436% | 241% | 176% | 109% |
| Bmk -ve Days | 10 | 25 | 36 | 64 | 121 | 325 |
| Stock -ve Days | 10 | 23 | 32 | 59 | 118 | 377 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with LEXX | |
|---|---|---|---|---|
| LEXX | -56.9% | 126.7% | -0.04 | - |
| Sector ETF (XLV) | 33.1% | 16.7% | 1.53 | 8.9% |
| Equity (SPY) | 13.2% | 12.9% | 0.68 | 12.4% |
| Gold (GLD) | 1.0% | 28.8% | 0.03 | 5.4% |
| Commodities (DBC) | 35.9% | 21.2% | 1.34 | -7.8% |
| Real Estate (VNQ) | 14.3% | 14.1% | 0.70 | 7.0% |
| Bitcoin (BTCUSD) | -28.2% | 43.4% | -0.65 | 15.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with LEXX | |
|---|---|---|---|---|
| LEXX | -41.0% | 99.9% | -0.06 | - |
| Sector ETF (XLV) | 9.3% | 15.3% | 0.40 | 9.2% |
| Equity (SPY) | 12.5% | 17.2% | 0.55 | 14.9% |
| Gold (GLD) | 17.3% | 19.1% | 0.73 | 5.5% |
| Commodities (DBC) | 8.0% | 19.6% | 0.29 | 2.6% |
| Real Estate (VNQ) | 1.8% | 18.9% | -0.01 | 8.7% |
| Bitcoin (BTCUSD) | 5.5% | 51.5% | 0.29 | 11.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with LEXX | |
|---|---|---|---|---|
| LEXX | -22.7% | 104.4% | 0.24 | - |
| Sector ETF (XLV) | 12.5% | 16.8% | 0.61 | 9.3% |
| Equity (SPY) | 15.4% | 18.0% | 0.73 | 13.2% |
| Gold (GLD) | 11.9% | 16.5% | 0.59 | 2.9% |
| Commodities (DBC) | 7.4% | 18.1% | 0.33 | 5.9% |
| Real Estate (VNQ) | 5.7% | 20.7% | 0.23 | 9.3% |
| Bitcoin (BTCUSD) | 61.0% | 66.2% | 1.01 | 10.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/3/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 05/31/2026 | 07/13/2026 | 10-Q |
| 02/28/2026 | 04/13/2026 | 10-Q |
| 11/30/2025 | 01/13/2026 | 10-Q |
| 08/31/2025 | 11/28/2025 | 10-K |
| 05/31/2025 | 07/14/2025 | 10-Q |
| 02/28/2025 | 04/14/2025 | 10-Q |
| 11/30/2024 | 01/10/2025 | 10-Q |
| 08/31/2024 | 11/26/2024 | 10-K |
| 05/31/2024 | 07/12/2024 | 10-Q |
| 02/29/2024 | 04/09/2024 | 10-Q |
| 11/30/2023 | 01/12/2024 | 10-Q |
| 08/31/2023 | 11/20/2023 | 10-K |
| 05/31/2023 | 07/14/2023 | 10-Q |
| 02/28/2023 | 04/14/2023 | 10-Q |
| 11/30/2022 | 01/17/2023 | 10-Q |
| 08/31/2022 | 11/28/2022 | 10-K |
| Report Date | Filing Date | Filing |
|---|---|---|
| 05/31/2026 | 07/13/2026 | 10-Q |
| 02/28/2026 | 04/13/2026 | 10-Q |
| 11/30/2025 | 01/13/2026 | 10-Q |
| 08/31/2025 | 11/28/2025 | 10-K |
| 05/31/2025 | 07/14/2025 | 10-Q |
| 02/28/2025 | 04/14/2025 | 10-Q |
| 11/30/2024 | 01/10/2025 | 10-Q |
| 08/31/2024 | 11/26/2024 | 10-K |
| 05/31/2024 | 07/12/2024 | 10-Q |
| 02/29/2024 | 04/09/2024 | 10-Q |
| 11/30/2023 | 01/12/2024 | 10-Q |
| 08/31/2023 | 11/20/2023 | 10-K |
| 05/31/2023 | 07/14/2023 | 10-Q |
| 02/28/2023 | 04/14/2023 | 10-Q |
| 11/30/2022 | 01/17/2023 | 10-Q |
| 08/31/2022 | 11/28/2022 | 10-K |
| 05/31/2022 | 07/14/2022 | 10-Q |
| 02/28/2022 | 04/11/2022 | 10-Q |
| 11/30/2021 | 01/14/2022 | 10-Q |
| 08/31/2021 | 11/29/2021 | 10-K |
| 05/31/2021 | 07/15/2021 | 10-Q |
| 02/28/2021 | 04/14/2021 | 10-Q |
| 11/30/2020 | 01/14/2021 | 10-Q |
| 08/31/2020 | 10/15/2020 | 10-K |
| 05/31/2020 | 06/30/2020 | 10-Q |
| 02/29/2020 | 04/03/2020 | 10-Q |
| 11/30/2019 | 01/09/2020 | 10-Q |
| 08/31/2019 | 11/14/2019 | 10-K |
Insider Activity
Updated 4/26/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Bunka, Christopher | Private Holding Company | Buy | 7302025 | 0.91 | 11,900 | 10,866 | 257,414 | Form | |
| 2 | Bunka, Christopher | Private Holding Company | Buy | 7302025 | 0.92 | 15,600 | 14,375 | 248,816 | Form | |
| 3 | McKechnie, William Edward | Direct | Buy | 7302025 | 0.91 | 5,000 | 4,532 | 16,487 | Form | |
| 4 | Docherty, John Martin | President & CSO | Direct | Buy | 7302025 | 0.93 | 5,376 | 4,989 | 4,989 | Form |
| 5 | Carle, Vanessa | Secretary | Direct | Buy | 7302025 | 0.91 | 750 | 682 | 682 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Bunka, Christopher | Private Holding Company | Buy | 7302025 | 0.91 | 11,900 | 10,866 | 257,414 | Form | |
| 2 | Bunka, Christopher | Private Holding Company | Buy | 7302025 | 0.92 | 15,600 | 14,375 | 248,816 | Form | |
| 3 | McKechnie, William Edward | Direct | Buy | 7302025 | 0.91 | 5,000 | 4,532 | 16,487 | Form | |
| 4 | Docherty, John Martin | President & CSO | Direct | Buy | 7302025 | 0.93 | 5,376 | 4,989 | 4,989 | Form |
| 5 | Carle, Vanessa | Secretary | Direct | Buy | 7302025 | 0.91 | 750 | 682 | 682 | Form |
| 6 | Christopher, Richard | Chief Executive Officer | Direct | Buy | 7302025 | 0.91 | 15,000 | 13,641 | 59,111 | Form |
Lexaria Bioscience — Investor Video Playlist
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.